Search results for "renal replacement therapy"

showing 5 items of 45 documents

INT-009 Pharmacokinetics of linezolid and meropenem in intensive care unit patients receiving continuous renal replacement therapy

2016

Background Intensive care unit (ICU) patients often suffer from infections and acute renal failure and might need continuous renal replacement therapy commonly applied by veno-venous hemodialysis (CVVHD) or hemodiafiltration (CVVHDF). In this case there are no dosage recommendations in the product informations of antibiotics and literature data are scarce. The risk for therapy failure, development of resistance and adverse drug effects is elevated. Purpose Aim of the presented study was to find out if standard therapy of Linezolid (LZ) and Meropenem (MP) results in adequate plasma levels in surgical ICU patients receiving CVVHD(F). Materials and Methods Surgical ICU patients receiving CVVHD…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.drug_classmedicine.medical_treatmentAntibioticsMeropenemIntensive care unitSurgerylaw.inventionchemistry.chemical_compoundchemistryPharmacokineticslawTherapeutic drug monitoringAnesthesiaLinezolidmedicineRenal replacement therapyHemodialysisGeneral Pharmacology Toxicology and Pharmaceuticsbusinessmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency

2020

Oral anticoagulation (OAC) is effective at preventing and treating thromboses and thromboembolism in patients with normal renal function. We aimed to research the impact of severe renal failure (RF) on patient outcome and to determine the potential benefit of caring for these patients in a specialized coagulation service (CS). A total of 1516 usual medical care patients and 756 CS-managed patients of the thrombEVAL multicenter (21 centers), prospective, cohort study (NCT01809015) were analyzed in a 3-year follow-up. Patients with RF (serum creatinine &gt

medicine.medical_specialtymedicine.medical_treatmentlcsh:MedicineRenal function030204 cardiovascular system & hematologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineRenal replacement therapyAdverse effectcoagulation serviceOral anticoagulationoral anticoagulationCreatininevitamin k-antagonistsbusiness.industrylcsh:RHazard ratioGeneral Medicineadverse eventschemistrybusinesschronic kidney diseaseCohort studyJournal of Clinical Medicine
researchProduct

Zero-contrast percutaneous coronary interventions to preserve kidney function in patients with severe renal impairment and hemodialysis subjects

2019

Introduction Zero-contrast percutaneous coronary intervention (zero-PCI) is a new method for prevention of contrast-induced acute kidney injury (AKI) in patients with chronic kidney disease (CKD). However, evidence for its feasibility, safety and clinical utility is limited to reports of single cases or series of patients. Aim To present outcomes of zero-PCI in patients with severe CKD, including hemodialysis subjects, who were treated with this procedure in order to preserve their renal function. Material and methods Twenty-nine zero-PCIs were performed, mostly as a staged procedure, in 20 patients with advanced CKD. In this group, 4 patients were treated with hemodialysis but presented pr…

medicine.medical_specialtyzero-contrast percutaneous coronary interventionmedicine.medical_treatmentContrast-induced nephropathylcsh:MedicineRenal function030204 cardiovascular system & hematologyRevascularizationurologic and male genital diseasesrenal insufficiency03 medical and health sciences0302 clinical medicine0502 economics and businessmedicineRenal replacement therapyOriginal Paperbusiness.industrylcsh:R05 social sciencesAcute kidney injuryPercutaneous coronary interventionmedicine.diseaseSurgeryacute kidney injurycontrast-induced nephropathy050211 marketingHemodialysisCardiology and Cardiovascular MedicinebusinessKidney diseasePostępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
researchProduct

Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support: Study Protocol for a Single Center, Sin…

2021

Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is the rescue treatment proposed to patients with refractory cardiogenic shock. The VA-ECMO implantation promotes inflammation and ischemia-reperfusion injuries through the VA-ECMO flow, causing digestive mucosa barrier disrupture and inducing translocation of bacterial wall components—Lipopolysaccharides (LPS) with further inflammation and circulatory impairment. LPS is a well-studied surrogate indicator of bacterial translocation. Oxiris membrane is a promising and well-tolerated device that can specifically remove LPS. The main study aim is to compare the LPS elimination capacity of Oxiris membrane vs. a non-absorban…

medicine.medical_treatmentcontinuous renal replacement therapyheart failureoxirisContext (language use)InflammationCardiovascular Medicineartificial membranelaw.inventionStudy ProtocolRandomized controlled triallawmedicineClinical endpointExtracorporeal membrane oxygenationDiseases of the circulatory (Cardiovascular) systemRenal replacement therapycytokines/bloodbusiness.industryCardiogenic shockcardiogenic shockextracorporeal membrane oxygenationmedicine.diseasesurgical procedures operativeendotoxin/bloodRC666-701AnesthesiaHeart failuremedicine.symptomCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct